HIGHLIGHTS
- who: Jean-Franu00e7ois Rossi from the Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland Kanazawa Medical University, Japan have published the research work: Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling, in the Journal: (JOURNAL)
- what: The model shows that the use of siltuximab and tocilizumab on alternate days increases the probability of achieving complete blockade of IL-6 signalling versus monotherapy with either mAb alone. The analysis shows heterogeneous baseline levels of CRP in patients with iMCD, and that patients with high baseline levels have significantly increased CRP levels within a week of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.